The record-setting Alexandria lab lease in San Diego showcases how biotech has few big tenants left to take empty spaces.

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Dr. Magdalena Renne, a leading expert in 3D organoid systems, details how her team has overcome longstanding barriers in ...

The pharmaceutical industry’s move toward increased U.S.-based manufacturing is changing the landscape of career ...

On Monday, 1256 stocks advanced, 2881 declined and 162 remained unchanged on Bombay Stock Exchange with advance decline ratio ...

In July 2025, Novartis Pharmaceuticals announced a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

In this article, you’ll find some of the top content that was published on LCGC this week, including an ASMS 2025 retrospective and an overview of microplastic research.

This month’s executive moves span a diverse range of organisations – from CDMOs and genomics platforms to diagnostics and ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

Longer treatment duration, not having diabetes, and using semaglutide are among the factors linked to better weight reduction over 12 months.

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...